NCT00619476

A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)

Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 376 (actual)
• Sponsor: XenoPort, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).

Detailed description

The primary purpose of study PXN110748 was to evaluate efficacy and safety of 3 fixed doses of GEn in the treatment of PHN.

Conditions

• Neuralgia, Postherpetic

Interventions

Type	Name	Description
DRUG	GEn 1200mg/day	gabapentin enacarbil 1200mg/day
DRUG	GEn 2400mg/day	gabapentin enacarbil 2400mg/day
DRUG	GEn 3600mg/day	gabapentin enacarbil 3600mg/day
DRUG	Placebo	placebo

Timeline

• Start date: 2008-02-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2008-02-21
• Last updated: 2013-07-22
• Results posted: 2011-05-20

Locations

83 sites across 2 countries: United States, Canada